H.C. Wainwright Thinks Capricor Therapeutics’ Stock is Going to Recover


H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Capricor Therapeutics (NASDAQ: CAPR) today and set a price target of $8.60. The company’s shares closed yesterday at $1.20, close to its 52-week low of $0.96.

Pantginis wrote:

“Valuation and potential impediments to achieving it. We reiterate our Buy rating and $8.60 price target. Our price target is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, CAP-1002 in DMD patients. We believe this method is appropriate in capturing the value of the clinical stage pipeline by allowing us to flex multiple assumptions, including chance of success, peak sales estimates, and year of commercial launch.”

According to TipRanks.com, Pantginis has currently no stars on a ranking scale of 0-5 stars, with an average return of -12.4% and a 31.3% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.

Capricor Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $7.80.

See today’s analyst top recommended stocks >>

The company has a one-year high of $4.25 and a one-year low of $0.96. Currently, Capricor Therapeutics has an average volume of 239.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts